SL Science Holding Limited
SLBTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSL Science Holding Limited manufactures cosmetic skin care and scalp care products. The $644.9M market capitalization puts SLBT squarely in small-cap range for its industry. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Market Cap
$644.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.01
EPS (Fwd)
—
ROE
—
ROA
—
Cash
$3.4M
Total Debt
$305,669
Free CF
—
52W Change
-88.9%
Annual Financials
Cash vs Debt
Where SLBT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SLBT finished 70.23% below its 150-day moving average ($5.14) and 76.50% below its 200-day moving average ($6.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLBT overbought or oversold?
At the October 20, 2026 close, SLBT's RSI(14) was 15.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SL Science Holding Limited holds $3.4M in cash against $306K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Revenue has been uneven over recent years, ranging from $879K to $2.2M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SL Science Holding Limited's trajectory.